9 Comments
User's avatar
Melissa's avatar

People increasingly sickened and/or dying of preventable diseases pretty much speaks for itself in terms of vaccine efficacy. Covid and flu obviously still need to be defended against with safe and efficient vaccines especially for those most vulnerable and/or with chronic disease conditions.

It is absolutely unacceptable for govt. officials regardless of their (ill appointed) status to tweak any data collection or change any professional documentation to align with their unscientifically dangerous and conspiracy-based supposed public health guidance.

Florent Beuyet's avatar

Your correction of "prevented" to "associated with" is the most important sentence in this piece — and it isn't just style. On the pharmacy counter, we live inside that distinction every day: every prescribing-information section says what a drug is indicated for, not what it "prevents," precisely because observational data can't bear the verb. The Quebec authors overreached; you caught it.

What jumped out at me clinically was the waning curve hiding behind the headline 57%: about 70% soon after the booster, roughly 30% at six months, with the confidence interval flirting with zero. That's the number that actually changes a counseling conversation, because it expires faster than the recommendation does. The authors' own caveat — that repeated vaccination is "unlikely to provide substantial incremental benefit" for long COVID while saying nothing about severe disease — deserves to be quoted more often than it will be.

One question I keep turning over: did the month-long VFC ordering delay and the "shared clinical decision-making" framing effectively turn a logistics failure into a recommendation failure? By the time ordering opened on September 23, the hesitancy architecture was already built.

Florent Beuyet's avatar

The most valuable sentence here is the quiet correction of the authors' own language — "associated with" rather than "prevented," "contributes to" rather than "confirms." That distinction is exactly what gets lost when these findings travel. As a pharmacist, the finding I reach for most at the counter is the hybrid-immunity one: 80–90% lower long-COVID risk with vaccination plus prior infection is the clearest answer I have for "I already had COVID, why bother with the booster?" And the waning curve — ~70% protection soon after the shot sliding toward ~30% at six months — makes the seasonal-booster case better than any mandate ever could. One question I'm left with: with the NIH opening a vaccine-injury research center, will its case definitions and data be published openly enough that both skeptics and supporters have to argue from the same evidence?

schneebaum's avatar

What can be done to help people with long Covid?

Mychel Vandover's avatar

I got my Covid and flu shots about a week ago and received a text from the CDC Vaccine tracker (sorry, forgot the name, maybe VCAP?) for the first time in a few years about whether I got the vaccine about getting it and how I felt. Given who is currently in charge, I am exceedingly hesitant to answer. Should I answer anyway or is my fear here rational?

Paul John M.'s avatar

Bravo! Finally an attempt to convey relative risk reduction with the 57% graphic and it's much needed.

But the 57% estimate needs clearer context: it compares three to five doses with two doses received at least six months earlier. And it includes protection against getting COVID in the first place. (If an intervention reduces hospitalizations, it also reduces opportunities for hospital-acquired infections. If vaccination prevents the infection, it also prevents the long COVID that could follow.)

So this is NOT a 57% reduction in long COVID among people who already caught COVID.